No Data
No Data
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulp
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise
Eagle Pharmaceuticals (EGRX) shares climbed 9% in recent trading after the company said Monday that it will present phase III trial data showing that intravenous amisulpride may sustain an antiemetic
Express News | Eagle Pharmaceuticals To Present Additional Data From Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference
HROW, HCAT and EGRX Are Among After Hour Movers
Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays